Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
clinical trials
9
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
9
×
boston top stories
biotech
new york blog main
new york top stories
cancer
deals
fda
sanofi
amgen
boston
eli lilly
indiana blog main
indiana top stories
ipo
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
cancer drugs
detroit blog main
detroit top stories
flatiron health
general atlantic
hepatitis b
investing
national
new york
non-small cell lung cancer
novartis
raleigh-durham blog main
raleigh-durham top stories
revolution medicines
roche
What
medicines
9
×
cancer
drug
ipo
research
announced
approval
ceo
deal
fda
gets
new
proteins
revolution
way
abandoning
aces
acquisitions
ago
aim
amgen
baggage
big
bio
biotechs
blueprint
boost
cancer’s
candidate
candidates
central
change
cholesterol
class
cns
collabs
community
companies
covid
currently
Language
unset
Current search:
medicines
×
" clinical trials "
×
" san francisco top stories "
×
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
With OneOncology, Flatiron and Cancer Docs Aim to Boost Community Care
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines